We are pleased to announce that the first Impact Factor of CJC is 2.155 !
Last year, the Chinese Journal of Cancer (CJC) was accepted in the Science Citation Index Expanded (SCI-E) by Thomson Reuters.
It has then been granted an Impact Factor of 2.155 for the of 2014, reflecting the citations during the year 2014 of articles published in 2012 and 2013.
Cases of lung cancer in China are rising, but why is this? Editors of a new series on lung cancer, Li Yan and Wei Zhang, explain why occurrence of lung cancer is increasing in China and the work that is being done to prevent this.
Long time USCACA supporter and advisor, Dr. George Wilding, appointed vice provost for clinical and interdisciplinary research at MD Anderson Cancer Center
----
HOUSTON ― The University of Texas MD Anderson Cancer Center is pleased to announce the appointment of George Wilding, M.D., as vice provost for clinical and interdisciplinary research. Dr. Wilding is a prominent prostate cancer physician-scientist who directed the University of Wisconsin’s Carbone Cancer Center (UWCCC) for 12 years. His appointment at MD Anderson begins Sept. 1.
Philadelphia, PA — (May 6, 2015) On April 19, 2015, more than 100 cancer researchers worldwide from academia, industry, and government agencies attended the 7th Annual USCACA Meeting at AACR 2015, organized by a committee consisting of sixteen Executive Members of the USCACA.
Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer
Occam Global is a strategic executive search firm with substantial experience serving entrepreneurial companies in the Healthcare and Technology sectors.
Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
SHENZHEN, China, Jan. 09, 2015 /PRNewswire/ -- Chipscreen Biosciences today announced regulatory approval of Chidamide (Epidaza®), the world first orally administrated and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA).
